Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma ...

Pfizer’s Padcev plus Keytruda combo shows significant survival gains in muscle‑invasive bladder cancer and could become ...